1380 - BRCA mutation testing to determine eligibility for olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer

Page last updated: 14 February 2017

Application Detail

Description of Medical Service

Genetic testing for BRCA1 and BRCA2 mutations in patients with platinum-sensitive relapsed ovarian cancer, to determine PBS eligibility for treatment with olaparib (co-dependent technology)

Description of Medical Condition

Ovarian cancer is the tenth most common cancer in Australian women, and the second most common gynaecological cancer. The symptoms for ovarian cancer tend to be vague and non-specific. The majority of women with ovarian cancer are diagnosed at an advanced stage after the tumour has spread to other organs, with the prognosis associated with advanced ovarian cancer being limited.

Reason for Application

New MBS item

Medical Service Type

Co-dependent technology

Previous Application Number

Not Applicable

Associated Documentation

Application Form

-

PICO Confirmation

Final Protocol - Ratified (PDF 402 KB)
Final Protocol - Ratified (Word 663 KB)

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 165 KB)
Public Summary Document (Word 118 KB)

Meetings for this Application

PASC

14 - 15 August 2014
11 - 12 December 2014

ESC

10 - 11 February 2016

MSAC

30 - 31 March 2016
24 - 25 November 2016